Lead Inventor:
Riccardo Dalla-Favera M.D.
Targeted Immunotherapies for Lymphona that Limit Side Effects
Lymphoma is the most common blood cancer, of which B-cell non-Hodgkin lymphomas comprise the largest category. Standard treatments for lymphoma involve chemotherapy and radiation therapy, both of which have extensive side effects. However, targeted immunotherapies are also being developed with the intention of limiting side effects. Treatment decisions and prognosis depend on accurate classification and staging of the lymphoma which, in turn, depend on the use of biomarkers.
BCL-6 Gene, BCL-6 Antibody and Diagnostic Methods for Lymphoma
BCL-6 is an oncogenic transcriptional repressor implicated in many types of B cell lymphoma. The technology includes the BCL-6 gene, BCL-6 antibody, and diagnostic methods using both of the above. Gene rearrangements of BCL-6 occur in 30-40% of diffuse large B-cell lymphomas and 6-15% of follicle center lymphomas. In addition, immunohistochemical detection of BCL-6 protein is useful for the classification, staging, and prognosis of B cell lymphomas.
Applications:
• Provides a molecular and tissue diagnostic method for B cell lymphoma.
• Can be used as a companion biomarker in developing novel therapies for B cell lymphoma.
• Provides a potential assay for lymphoma drug screening.
Advantages:
• BCL-6 is an important molecular diagnostic and tissue diagnostic biomarker for multiple B-cell lymphoma types.
• BCL-6 is the most commonly involved oncogene in diffuse large B-cell lymphoma.
• BCL-6 may play a role in other cancers, such as breast cancer and multiple myeloma.
Patent Status: Patents Issued (US5641672, US5882858, US6174997, US6783945) ~ seel links below.
Licensing Status: Available for Licensing and Sponsored Research Support
Publications: Bihui H. Ye et al,
Cloning of bcl-6, the Locus Involved in Chromosome Translocations Affecting Band 3q27 in B-cell Lymphoma. (1993) Cancer Research 53: 2732
